Pfizer's COVID-19 vaccine shows 95% efficacy in phase 3 trial

Pfizer announces that its Corona vaccine seems to be 95% effective against COVID-19. Pfizer Pharma claims that phase 3 of the study has met all primary efficacy endpoint. According to the pharma major, the study involved 170 confirmed coronavirus cases and the vaccine candidate, BNT162b2, demonstrated 95% efficacy in treating the disease beginning 28 days after the first dose.

Importantly, Pfizer announced that its vaccine candidate has also achieved the safety milestone which is required by the US FDA to grant Emergency Use Authorization (EUA). “To date, no serious safety concerns related to the vaccine candidate have been reported,” the company said on Twitter.